Rapamycin in Frail Older Subjects with Heart Failure with Preserved Ejection Fraction
What this study shows
Trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction (HFpEF), from a Mayo Clinic/UW-Madison team including senolytics/mTOR-aging researchers Kirkland and Lamming; abstract not yet available (ahead-of-print).
At a glance
| Evidence type | H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H. |
| Study type | 2 - Human Clinical Trial |
| Model system | Human (frail older adults with HFpEF) |
| Journal | Mayo Clinic Proceedings |
| Year | 2026 |
| Peer reviewed | Yes |
| Record last updated | 2026-09-23 |
| Source | DOI 10.1016/j.mayocp.2026.09.006 · PMID 42759606 |